H.C. Wainwright raised the firm’s price target on Akero Therapeutics (AKRO) to $72 from $50 and keeps a Buy rating on the shares after the ...

H.C. Wainwright analyst Patrick Trucchio raised the firm’s price target on uniQure (QURE) to $70 from $25 and keeps a Buy ...

H.C. Wainwright reiterated a Buy rating on shares of GH Research PLC (NASDAQ:GHRS), with a price target of $40.00. Currently ...

About H.C. Wainwright & Co. H.C. Wainwright is a full-service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across ...

Lexaria Bioscience (NASDAQ:LEXX – Free Report) had its price target trimmed by HC Wainwright from $10.00 to $7.00 in a report issued on Friday,Benzinga reports. The firm currently has a buy rating on ...

Analysts at HC Wainwright boosted their FY2024 earnings estimates for Precigen in a research report issued to clients and investors on Thursday, January 23rd. HC Wainwright analyst S. Ramakanth now ...

H.C. Wainwright raised the firm’s price target on ArriVent Biopharma (AVBP) to $39 from $36 and keeps a Buy rating on the ...

H.C. Wainwright raised the firm’s price target on Monopar Therapeutics (MNPR) to $40 from $22 and keeps a Buy rating on the ...

H.C. Wainwright launched its coverage of eczema drug developer Corvus Pharmaceuticals (NASDAQ:CRVS) with a Buy recommendation and an $11 per share target on Thursday, despite an over 38% drop ...

H.C. Wainwright lowered the firm’s price target on Jasper Therapeutics (JSPR) to $40 from $60 and keeps a Buy rating on the shares after the company announced initial data from the BEACON study ...

H.C. Wainwright initiated coverage of MetaVia (MTVA) with a Buy rating and $12 price target The company’s DA-1726 is a novel oxyntomodulin analogue designed as a dual agonist targeting glucagon ...

BTCS Inc. (Nasdaq: BTCS) (“BTCS” or the “Company”), a leader in blockchain infrastructure and technology, has announced its ...